A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice

@article{Adams2004AST,
  title={A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice},
  author={Gregory P. Adams and Calvin C. Shaller and Ekaterina Dadachova and Heidi H. Simmons and Eva M. Horak and Abohawariat Tesfaye and Andres J Klein-Szanto and James D Marks and Martin W Brechbiel and Louis M. Weiner},
  journal={Cancer Research},
  year={2004},
  volume={64},
  pages={6200 - 6206}
}
Antitumor diabody molecules are noncovalent single-chain Fv dimers that recapitulate the divalent binding properties of native IgG antibodies. Diabodies are capable of substantial accumulation in tumor xenografts expressing relevant antigens in immunodeficient mouse models. With a Mr of approximately 55,000, diabodies are rapidly cleared from the circulation, resulting in tumor-to-blood ratios that significantly exceed those achieved early after the administration of monoclonal antibodies. We… Expand
Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies
TLDR
Findings indicate that diabody molecules can be effective agents for targeted radioimmunotherapy of solid tumors using powerful, short-lived α-emitting radioisotopes. Expand
Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
TLDR
The data indicate that the PEGylated anti-CD22 diabody may have potential for extending the repertoire of radiopharmaceuticals for the treatment of patients with B-NHL. Expand
Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft
TLDR
Pretargeting increases the amount of radioactivity delivered to colorectal tumors sufficiently to improve the therapeutic index and responses as compared with conventional radioimmunotherapy. Expand
Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons
TLDR
Abs labeled with nuclides emitting low-energy electrons, such as 111In, can be effective therapeutic agents against microscopic s.c. tumors. Expand
Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody
Purpose: A disadvantage of conventionally radioiodinated monoclonal antibodies (mAb) for cancer therapy is the short retention time of the radionuclide within target cells. To address this issue, weExpand
Native MAG-1 antibody almost destroys human breast cancer xenografts
TLDR
Examination of the ability of 90Yttrium-labeled and native MAG-1 to affect the growth in nu/nu mice of cancer xenografts that were estrogen-responsive and triple-negative revealed they had undergone very extensive necrosis. Expand
Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody
TLDR
Evidence is provided that the growth rate of SCLC tumors can be extensively reduced by treatment with MAG-1 antibody, and that a humanized form of this antibody could, in future, be potentially used for targeting therapy onto recurrent SclC in patients. Expand
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
TLDR
The present results show that radiolabeled synthetic DOTA-Z(HER2:342-pep2) has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas. Expand
Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate
TLDR
Compared with other L19-basedRadioimmunoconjugates, I-131-L19-SIP is characterized by superior antitumor efficacy and toxicity profile in the F9 teratocarcinoma animal model, indicating that ED-B fibronectin-targeted radioimmunotherapy using I- 131-L 19-Sip has potential to be applied to treatment of solid cancers. Expand
166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.
TLDR
It is concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half- life of (166)Ho to deliver the tumoricidal absorbed dose to the tumor. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.
TLDR
These data demonstrate that, following their i.v. administration, both monovalent and divalent forms of 741F8 sFv are specifically retained by SK-OV-3 tumors, and precludes the possibility that passive diffusion and pooling in the tumor interstitium contributes significantly to long-term tumor localization. Expand
Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.
TLDR
The physical half-life of (213)Bi may be too brief to be effectively paired with systemically-administered diabody or scFv molecules. Expand
Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
TLDR
A cold antibody therapeutic effect was unexpected at this dose level (3 microg), and it may be possible that in some animals that 3 microg of antibody of (90)Y-labeled DOTA-4D5 augmented tumor growth reduction. Expand
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
TLDR
The diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has promise as a delivery vehicle for therapeutic agents. Expand
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.
  • R. Schier, J. Marks, +7 authors L. Weiner
  • Chemistry, Medicine
  • Immunotechnology : an international journal of immunological engineering
  • 1995
TLDR
These results are the first in vivo biodistribution studies using an sFV isolated from a non-immune human repertoire and confirm the specificity of sFv produced in this manner. Expand
Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
  • H. Kobayashi, C. Wu, +7 authors M. Brechbiel
  • Chemistry, Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1998
TLDR
In vivo stability and biodistribution of four isomers of 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaaceti c acid (CHX-DTPA), a recently developed backbone-substituted derivative of DTPA, are evaluated, indicating that differences in stereochemistry can greatly influence stability of radionuclide in the chelate. Expand
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.
  • A. Wu, W. Chen, +7 authors J. Shively
  • Chemistry, Medicine
  • Immunotechnology : an international journal of immunological engineering
  • 1996
TLDR
Non-covalent dimers of scFV are stable, easy to produce and show excellent targeting as compared to monomeric scFv, probably due to increased mass and valency. Expand
Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
TLDR
With 131I-labeled IgG and fragments there is greater flexibility to permit tumoricidal doses without excessive toxicity to the normal tissues, and radiation dose estimates derived from these studies suggest that at the maximal tolerated dose131I-NP-4 IgG would deliver 5.9 times the dose to the tumor as 90Y-labeling NP- 4 IgG. Expand
Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice.
TLDR
There is a recognition phenomenon in mice for this murine monoclonal antibody, p-isothiocyanatobenzyl-EDTA, which forms complexes with 111In that are stable in vivo and shows a dose dependent uptake by the liver. Expand
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
TLDR
High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable. Expand
...
1
2
3
4
...